<DOC>
	<DOCNO>NCT02260609</DOCNO>
	<brief_summary>A multicenter , open-label , single-arm study evaluate safety efficacy GrafixCORE® treatment complex diabetic foot wound expose tendon and/or bone .</brief_summary>
	<brief_title>GrafixCORE® : Open-Label Study Evaluate Safety Efficacy GrafixCORE® Complex Diabetic Foot Wounds</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>1 . Between 18 year 85 year age inclusive , date screen 2 . Confirmed diagnosis Type I Type II Diabetes 3 . Index wind grade Texas Classification System Grade IIIII , Stage A C ( without active infection ) 4 . Wound locate foot malleoli 5 . Wound accommodates three ( 3 ) 5 cm x 5 cm piece GrafixCORE® completely cover wound 6 . Patient 's wound extend dermis subcutaneous tissue evidence expose muscle , tendon , bone , and/or joint capsule 7 . Patient adequate circulation foot document either : Ankle Brachial Index ( ABI ) ≥ 0.5 ≤ 1.2 , In patient noncompressible ankle vessel , Toe BP ≥ 40 mmHg TcPO2 &gt; 30 mmHg , Skin perfusion pressure &gt; 30 mmHg 1 . Index Wound nondiabetic pathophysiology 2 . Gangrene present part affect foot 3 . Index Wound Charcot deformity 4 . The long dimension Index Wound exceed 15 cm Baseline Visit 5 . Patient glycated hemoglobin A1 ( HbA1c ) level &gt; 14 % 6 . Requiring intravenous ( IV ) antibiotic treat index wound infection enrollment 7 . Patient wound within 15cm Index Ulcer identify study consideration 8 . Patient receive oral parenteral corticosteroid , immunosuppressive cytotoxic agent 9 . Patient Human Immunodeficiency Virus ( HIV ) positive Acquired Immune Deficiency Syndrome ( AIDS ) 10 . Current evidence osteomyelitis , cellulitis , evidence infection include fever pu drainage wind site 11 . Patient active malignancy nonmelanoma skin cancer 12 . Patient 's random blood sugar &gt; 450 mg/dl screen 13 . Patient untreated alcohol substance abuse time screen , deem nonadherent protocol Investigator 14 . Pregnant woman 15 . Patient currently enrol participate another investigational device , drug , biological trial within 30 day screen 16 . Patient allergy primary secondary dressing material use trial 17 . Patient within last 14 day , currently undergo , plan wound treatment enzymes , growth factor , live skin , dermal substitute advance biological therapy 18 . In opinion Investigator , patient unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Complex Wound</keyword>
	<keyword>Diabetic Foot Ulcer</keyword>
	<keyword>DFU</keyword>
	<keyword>GrafixCORE</keyword>
	<keyword>Exposed tendon</keyword>
	<keyword>Exposed bone</keyword>
	<keyword>Allograft tissue</keyword>
</DOC>